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Sary A detailed casenote review was performed on 55 patients registered with testicular non-
seminomatous germ cel tumours (NSGCT) between 1983 and 1988 under the Scottish Cancer Registration
Scheme and who had died by 1992. Details ofall aspects ofclnical managemet lating to their NSGCT and
death details were extracted and summaised. An assesment was made on whether the patients' mana t
had been optimal. An analysis of 5 year survival rates by the five Scottish oncology centres demonstrated
significant differences between centres (range 70.4-94 2; x2 = 14.46, d.f. = 4, P = 0.006). Some patients in all
centres were assessed as having received suboptmal treatment, but two centres perform less well than the
other three. There is a suggestion that the number of patients treated subopfimally decreases with increasing
number of patients seen, but this does not reach statistical siificance.
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Testicular germ cell tumours were, for the period 1981-90,
the commonest cancer in Scotland in men aged under 40
(Sharp et al., 1993a). Five year relative survival rates for
testicular NSGCT in Scotland have unproved from 75.3%
for the years 1977-82 to 85.0% for 1983-87 (Sharp et al.,
1993b), largely due to the introduction of platinum-based
chemotherapy (Ellis and Sikora, 1987). The complete excision
of residual masses following chemotherapy is now accepted
practice with more experinced surgeons in this area more
likely to perform adequate resection (Ewing et al., 1987;
Hendry et al., 1987; Whillis et al., 1991). It has also been
suggested that results of therapy for this diease in Scotland
are better in centres where a large number of patients are
seen (Harding et al., 1993). In Scotland there are five
oncology centres, patients with NSGCT being treated in
them all. The audit was designed to assess if there was any
variation in the success of therapy across the country for this
usually curable cancer.
This audit, and those reported in the accompanying two
papers (Clarke et al., 1995; Howard et al., 1995) were part of
a Scottish National Audit assessing the appropriateness and
variation in manag t strategies and success of therapy
for testicular NSGCIT. The survival patterns of patients
registered between 1983 and 1988 were assessed and a
detailed casenote review performed ofthose patients who had
died.
Methods
Survival analysis
Details of all testicular NSGCT cases diagnosed between 1
January 1983 and 31 December 1988 were obtained from the
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Scottish Cancer Registration Scheme. Completeness ofregist-
ration and validity of diagnosis were checked by cross-
referring with oncology centre records and are reported in
the accompanying paper (Clarke et al., 1995). New registra-
tions not referred to oncology centres were excluded from the
survival analysis as their diagnosis had not been validated.
The end of the follow-up period was defined as 31
December 1992 and survival time was caculated from date
of diagnosis until death, or the end of follow-up. Actuarial
survival curves based on Kaplan-Mewer estimates were des-
cribed and the log rank chi-square test for differences in
survival rates alculated. These data are summarised by
means of the 5 year survival rates with associated standard
error. Deaths from causes other than the disease or its treat-
ment, as assessed by the reviewer in this study, were cen-
sored.
As numbers of patients in some health boards were small
these were grouped crudely according to population density
to investigate area of residence at diagnosis of cancer. A
priori the following groupings were defined (1) urban - Ayr-
shire and Arran, Argyll and Clyde, Fife, Forth Valley,
Lanarkshire and Tayside; (2) rural - Borders, Dumfries and
Galloway, Grampian, Highland, Orkney, Shetland and
Western Isles. Greater Glasgow and Lothian health board
areas were examined separately.
All statistical tests were performed using standard methods
(Armitage and Berry, 1987; Siegal and Castellan, 1988).
Casenote review ofdeadpatients
A casenote, and where necessary radiological reviw, was
performed on all new testicular NSGCT cancer registrations
between 1983 and 1988, with a date ofdeath recorded before
31 December 1992. Data were collcted onto a specially
designed proforma and included date offirst symptom, dates
of referral to hospitaL oncologist etc., histology, staging pro-
cedures, Marsden stage at presentation (Peckrham et al.,Teslkar NSGCT mobrl aui, Scot,d
GCW Howard etal
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details of surgery, radiotherapy, and chemotherapy, patient
compliance. surveillance and any relapse details.
Written causes of death, as detailed on death certificates,
were obtained from the Registrar General for Scotland for all
cases audited.
An assessment of the appropriateness of treatment and
comments on any aspect of treatment that might have
adversely affected the patient's outcome was made by the
reviewing clinician, who was from a different centre to where
the patient had been treated. These data were subsequently
assessed anonymously.
Peer review
Case summaries were produced, incorporating a synopsis of
the proforma data and Registrar General death data. These
summaries, without the reviewer's comments were circulated
to group members, who were asked to make a 'blind' assess-
ment of the patients' management commenting on the
'appropriateness of therapy'. These assessments and
associated comments, plus the reviewer's comments were col-
lated and queries checked before a meeting where each indi-
vidual case was discussed and an assessment of treatment
agreed by all group members. A decision was first made as to
whether treatment was 'optimal' (treatment strategy appro-
pnate and administered properly), or 'suboptimal' (delayed
diagnosis. lack of treatment strategy, inappropriate treatment
or treatment not delivered properly). Further assessments of
the cause of death for the 'optimal' group, and the area of
therapy considered 'suboptimal' with the effect on prognosis.
were made. Agreement in all cases was unanimous.
Results
Stud} group
Amongst 391 cases of testicular NSGCT diagnosed between
1983 and 1988, 57 were known to have died by 31 December
1992. This represents a crude mortality rate of 14.6 per 100
registrations. Eighty per cent of these died within 3 years of
starting treatment with all but two cases dying within 5
years. These two cases survived 7.9 and 8.6 years, both
ultimately dying of their disease.
Two deaths were excluded from the casenote review. The
first was a Scottish resident treated wholly in England; the
second case was excluded as both radiotherapy and general
hospital casenotes had been destroyed.
Fifty-one of the remaining 55 patients who died were
referred to oncology centres. Two of the four cases not
referred died within days of diagnosis; the other two were not
seen by oncologists but written and verbal advice was sought
from them.
Survival anali}sis
For this analysis 37 cases from the total of 391 were excluded
as information was incomplete. Thirty-two cases had not
been referred to oncology centres. the notes for two cases
could not be traced so the diagnosis could not be verified,
two cases were lost to follow-up so their vital status was
unknown and in a further case the health board of residence
at diagnosis was unknown. The four patients who died and
were not referred to oncology centres were also excluded.
Crude mortality rates for all causes and for testicular
NSGCT by oncology centre of treatment and groupings of
health board area of residence are shown in Table I. There
was evidence of a statistically significant association between
age and oncology centre (/- = 28.51, d.f. = 12, P 0.005),
and age and health board (jX = 16.77. d.f. = 9, P= 0.053)
(Table II). Patients seen at oncology centre A were on
average older than those treated elsewhere.
Summary 5 year survival rates and their associated stan-
dard errors are detailed in Table III for age at diagnosis,
oncology centre of treatment and health board area of
residence. Figure 1 depicts survival by oncology centre of
treatment in terms of actuarial survival curves (Kap-
lan-Meier). Patients aged 45 and over had poorer survival
than younger age groups but these differences are not statis-
tically significant (log-rank = 5.12, d.f. = 3, P = 0.163).
Different health board areas had similar survival during
the first year. but thereafter rates diverge and at 5 years
those resident in 'rural' boards had a poorer rate than
elsewhere. Over the whole follow-up period these differences
Table I Deaths among new cancer registrations bycentre oftreatment
and health board of residence Scotland 1983-88
All deaths Testicularr NSGCT
Number Rate per 100 Deaths Rate per 100
Centre
A 6 40.0 4 26.7
B 8 19.5 6 14.6
C 4 23.5 2 11.8
D 16 19.5 15 18.3
E 17 8.7 12 6.2
Health board
Greater Glasgow 9 11.4 7 8.9
Lothian 6 12.0 5 10.0
Urban 18 12.1 13 8.7
Rural 18 25.0 14 19.4
NGSCT. non-seminatomous germ-cell tumours.
Table II Median age at diagnosis (years) with range new cancer
registrations Scotland (1983-88)
Age Range
Oncology centre
A 37 21-72
B 27 16-83
C 26 17-40
D 32 17-60
E 28 1-63
Health board of residence
Greater Glasgow 27 1-63
Lothian 33 17-50
Urban 28 15-60
Rural 29.5 16-83
Table m Five year survival rate (%) with standard error
Total Survival Standard
patients rate error
Age treatment commenced
<25 102 91.9 21.4
25-34 158 91.0 16.8
35-44 62 83.3 25.7
45+ 28 81.2 39.6
Oncology centre
A 15 70.4 48.6
B 41 87.3 32.0
C 17 86.7 51.3
D 82 81.5 21.9
E 195 94.2 15.6
Health board of residence
Greater Glasgow 79 92.3 24.1
Lothian 50 89.8 29.9
Urban 149 91.0 17.5
Rural 72 81.1 23.5
All cases 350 89.1 11.3l WU.U
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Figre 1 Percentage survival of patients with NSGCT bv
oncology treatment centre.
approached statistical significance (log-rank r = 6.84. d.f. =
3, P = 0.077).
The greatest differences in survival were seen between
oncology centres of treatment. From 2 years after diagnosis
centre E (5 year survival 94.2%, s.e. = 15.6) has consistently
the highest survival and centre A (5 year survival 70.4%,
s.e. = 48.6) the lowest. In centre A and centre D. which had
the second lowest 5 year survival rate (81.5%. s.e. = 21.9) all
disease related deaths occurred in the 3 years following diag-
nosis. Differences in overall survival were statistically
significant (X: = 14.46. d.f. = 4 P = 0.006). The importance
of this variation in survival is not clear as prognostic group
and stage of disease at presentation is not known for surviv-
ing patients.
Survival and the overall number of patients seen in indi-
vidual centres are not statistically associated (Spearman's
rank correlation coefficient (r,) = 0.7, P>0.20). This may
relate to the small number of treatment centres.
Casenote review ofdeaths
The median wait from first hospital visit to seeing an
oncologist was 9 days, but in four cases there was a delay of
over 8 weeks. In the two longest delays, 174 and 293 days,
the symptoms were misdiagnosed on initial presentation at
hospital. The median wait from first seeing an oncologist to
non-surgical treatment was 8 days with seven patients having
to wait over 4 weeks. Two patients waited more than 8
weeks. In one case the CT scan was normal but markers were
raised, while in the other case markers started to rise but
chemotherapy was delayed until after Christmas.
The median time from first symptom to first hospital visit
for all deaths and NSGCT-specific deaths shows no statis-
tically significant differences between areas of residence at
diagnosis (Wilcoxon-Mann-Whitney test; rural health
boards vs all other health boards: (a) all deaths, =- 0.07;
(b) teratoma-specific deaths Z = 0.57).
Table IV details Marsden stage (Peckham et al., 1979) and
prognosis according to MRC criteria (Mead et al., 1992) at
presentation. Despite radiology and extra casenotes being
sought, in 16% of cases no stage could be allocated. There
are differences between oncology centres and health board
areas in the stage and prognostic groups of patients at pres-
entation but numbers are too small for meaningful inter-
pretation.
Eighty per cent of patients received chemotherapy but
documentation of primary chemotherapy was poor and it
was not always clear whether chemotherapy had been
administered as prescribed. A range of regimens were
observed and some deviations from prescription recorded.
Four cases initially placed on surveillance died: two from
their disease and two from unrelated causes.
In five cases no active treatment was administered and of
these, four died of uncontrolled progressive NSGCT. In two
cases a clinical judgment was made not to treat (one patient
was mentally retarded and the other was epileptic) and two
Tesclar NSGCT mxrty audi Scudand
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Tabl IV Oncology centre of treatment and health board area of
residence by Marsden stage and MRC prognostic group at presentation
among deaths included in casenote review
.Uarsden Poor
stage 4 (% 0 prognosis (% vTotal
Oncology centre
A 50.0 50.0 6
B 12.5 50.0 8
C 75.0 50.0 4
D 68.8 43.8 16
E 29.4 52.9 17
Not referred 25.0 25.0 4
Health board of residence
Greater Glasgow 22.2 55.6 9
Lothian 50.0 33.3 6
Urban 47.6 42.9 21
Rural 47.4 52.6 19
Total 43.6 36.4 55
Table V Peer assessment ofquality of therapy
.NwnVber of Percentage
Treatment cases ofcases
Optimal 28 50.9
Suboptimal
Delayed diagnosisitherapy 2 3.6
Poor therapeutic management 13 23.6
Poor patient compliance 6 10.9
Management suboptimal because of 4 7.3
other medical conditions
25 45.5
Insufficient data to assess 1 1.8
No treatment, death 5 days post 1 1.8
orchidectomy
Total 55 100.0
further patients died before treatment could be given. The
fifth died in a road traffic accident 5 days after diagnosis and
before treatment started.
Peer review
A summary of peer assessment of treatment is given in Table
V. Only 51% were considered to have received optimal treat-
ment. The most frequent reason for treatment being assessed
as suboptimal was 'poor therapeutic management'.
The 25 cases judged by the panel to have received subop-
timal treatment are documented by area and centre of treat-
ment in Table VI. There are notable differences between
centres (X2= 4.24. d.f. = 4, P>0.10) and health board area
(yj = 2.51, d.f. = 3. P>0.10), but these do not attain statis-
tical significance.
Table VII details the number of optimal and suboptimal
treatments by centre in relation to the total number of
patients treated. In this analysis suboptimal treatment is all
deaths described as such by the peer review and optimal is all
other patients (deaths and non-deaths) seen in the centre
during the study period. On this basis statistically significant
differences exist between centres (x2 = 17.02, d.f. = 4, P<
0.01). If cases where therapeutic management was criticised
are examined in a similar manner, differences between centres
are observed, but numbers in individual centres are too small
to perform valid statistical tests.
Figure 2 shows all suboptimally treated patients and those
receiving poor therapeutic management by number of
patients treated in a centre. This suggests optimal therapy is
delivered more frequently in centres seeing more patients, but
this is not statistically significant (Spearman's rank correla-
tion coefficient (rj) = 0.7, P>0.20 for percentage treated
..u
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Table VI Peer assessment ofquality oftherapy by oncology centre of treatment and health board area of
residence
Poor No Suboptinal
Optimal Suboptinal information treatment Total (%)
Oncology centre
A 2 4 0 0 6 66.7
B 2 6 0 0 8 75.0
C 3 1 0 0 4 25.0
D 10 5 0 1 16 31.3
E 9 7 1 0 17 41.2
Not referred 2 2 0 0 4 50.0
Health board of residence
Greater Glasgow 5 4 0 0 9 44.4
Lothian 4 1 0 1 6 16.7
Urban 12 8 1 0 21 38.1
Rural 7 12 0 0 19 63.2
Table VII Total patients by oncology centre of treatment and quality of therapy among
reviewed deaths
Category of Oncology centre
treatment A B C D E Total
All patients 15 41 17 82 195 350
Al suboptimal 4 6 1 5 7 23
(percentage oftotal) (26.7) (14.6) (5.9) (6.1) (3.6) (6.6)
Suboptimal (therapeutic management) 3 4 1 3 2 13
(percentage of total) (20.0) (9.8) (5.9) (3.7) (1.0) (3.7)
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and other health board areas
goal of this audit was to asses
deceased patients we did not c
nostic group at presentation fo
can therefore be taken in the
disease at diagnosis so interpre
poorer survival of 'rural' patier
that the majority of these patie
and B where 5 year survival wa
therefore not independent. It sh
are significant differences betwe
with centre A seeing on averag
than other centres.
In this analysis suboptimal
patients who died and had their
therapy was all other deaths plu
conservative estimate of suboptimal treatment as patients will
have survived who did not receive optimal therapy. The
allocation of deaths to optimal or suboptimal treatment
should be independent of stage and prognosis of disease at
presentation, and thus avoids the need for adjustment of
these and other confounding factors.
Of considerable concern is the number of patients who
were considered to have been treated in suboptimal fashion.
* In the four cases where a clinical judgement was made not to
i 0I Oi treat, the panel felt no further comment could be made. 00 120 140 160 180 200 Patients were categorised as having received suboptimal its treated in centre therapy if there were delays, poorpatient comphance or poor
s treated suboptimally by total therapeutic management. The main reasons for poor
all groups; 0, suboptimal therapeutic management were inappropriate chemotherapy or
A, coincident data point. inappropriately delvered chemotherapy and delayed surgical
referral. Although all centres had patients within the category
of suboptimal the proportion varied from 25-75%. Centres
A and B had the greatest percentage treated suboptimally
which may relate to the small and centre A also had the poorest 5 year survival rate. Rural
nd the small number of cases health boards of residence had fewer patients receiving
optimal therapy, but the majority of patients were treated in
centres A and B. In eight of the 12 rural cases treated
suboptimally therapeutic management is criticised. No
significant differences were observed between rural and all
other health board areas of residence in the time from first
n in the survival of patients symptom to first hospital treatment. There are no rural
.nt centres and between rural patients who were considered to have had suboptimal treat-
of residence. As the primary ment due to diagnostic or therapeutic delays, availability of
;s quality of management for service is not an apparent problem.
ollect data on stage or prog- Problems with defaulters were detailed and how to address
or living patients. No account these have been considered elsewhere (Howard et al., 1995).
survival data of the stage of In this mortality study 24% of the total patients who
tation must be cautious. The received suboptimal treatment were adjudged so because of
its may be related to the fact poor patient compliance. This highlights the need for greater
nts were treated at centres A counselling and psychological support at diagnosis and
s poorer, the two analyses are throughout treatment. There is perhaps a case for all patients
ould also be noted that there being routinely offered such assistance at diagnosis and at
en centres in age of patients critical times during treatment (e.g. at relapse, being placed
ye an older group of patients on surveillance or follow-up).
It has been suggested that results of therapy improve in
therapy was taken as those centres where more patients are seen (Harding et al., 1993;
r treatment criticised; optimal Stiller, 1994). This study shows that this is not necessarily the
is surviving patients. This is a case (centre C). Although there was a non-significant trend
vTesicular NSGCT morli audikScxdard
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for the number of patients treated suboptimally to decrease
with increasing numbers seen, the occurrence of one centre
with small numbers for suboptimal rates demonstrates there
may be ways of surmounting the problems of treating these
cases in small centres.
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